MedImmune Ventures

MedImmune is the global biologics research and development arm of AstraZeneca, dedicated to creating innovative medicines for unmet medical needs worldwide. Founded in 1988 and headquartered in Gaithersburg, Maryland, with an additional office in Mountain View, California, MedImmune focuses on pioneering research across several key therapeutic areas, including respiratory and inflammation conditions, cardiovascular and metabolic diseases, oncology, neuroscience, and infectious diseases. The organization engages in the research, development, manufacturing, and marketing of biologics, aiming to address critical healthcare challenges. MedImmune Ventures, established in 2002 as a venture capital arm of AstraZeneca, specializes in investing in life sciences and biotechnology companies at various stages of development, with a global reach that includes North America, Western Europe, and Asia Pacific. The firm typically invests around $7 million in companies that are involved in the development of therapeutics, vaccines, and medical technologies.

Ed Mathers

Executive Vice President, Corporate Development and Venture

Rivers Ph.D., Tyrell

Senior Associate

57 past transactions

Corvidia

Series B in 2018
Corvidia Therapeutics, Inc., a biotechnology company, develops precision cardiovascular therapies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. As of July 31, 2020, Corvidia Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.

G1 Therapeutics

Series C in 2016
G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

G1 Therapeutics

Series B in 2015
G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

MdBio Foundation

Grant in 2014
MdBio Foundation, Inc. has been providing innovative and effective bioscience education for middle and high school students since 1997. The non-profit, (501 c 3) organization is dedicated to providing bioscience awareness, education, and workforce development in the state of Maryland and beyond. The Foundation accomplishes this through a diverse set of programs, including their flagship program, MdBioLab, summer programs, and their leading-edge game-based learning platform, MdBioSphere. MdBio Foundation leverages its established, trusted relationships with private industry and school systems to create authentic, STEM-based career experiences on their mobile laboratory, MdBioLab, and through their youth camp, the Young Science Explorers Program (YSEP). These experiences provide a unique opportunity for students to observe first hand the types of careers they could pursue in STEM-related fields. Students and teachers who participate in MdBioLab and YSEP have increased access to information about bioscience industry products, research, and related careers through problem-based laboratory experiences that are aligned with local, state and, national curriculum standards. Commitment to Excellence: Since its inception, The MdBio Foundation has contributed more than $3.5M of their resources to these programs and will continue to invest more than $500K each year. The Foundation’s staff consists of talented and experienced educators and scientists who share a common goal of improving science education and creating a more accessible, educational experience.

Definiens

Acquisition in 2014
Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.

VentiRx Pharmaceuticals

Series B in 2014
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.

Allozyne

Acquisition in 2014
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.

Astria Therapeutics

Series B in 2013
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

G1 Therapeutics

Series A in 2013
G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

ADC Therapeutics

Series B in 2013
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Spirogen

Acquisition in 2013
Spirogen is a clinical stage biotechnology company specialising in novel, sequence-selective, DNA minor groove-binding molecules with potent therapeutic properties. Spirogen's principal technology involves modification of members of a group of naturally occurring antibiotics called pyrrolobenzodiazepines (PBDs). The company was founded in 2000, has 18 employees and is private equity funded.

Inotek Pharmaceuticals

Debt Financing in 2013
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Inotek Pharmaceuticals

Venture Round in 2013
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Amplimmune

Acquisition in 2013
Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune's scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients suffering from aberrant immunological conditions.

AlphaCore Pharma

Acquisition in 2013
AlphaCore Pharma operates as a biopharmaceutical company.

Astria Therapeutics

Venture Round in 2013
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

AGTC

Series B in 2012
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

Ambit Biosciences

Venture Round in 2012
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Cerapedics

Series C in 2012
Cerapedics is an orthobiologics company focused on developing its proprietary biomimetic small peptide molecule (P-15) for commercialization in spinal applications. The company was founded in 2001 and is headquartered in Westminster, Colorado.

Coferon

Series B in 2012
Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.

Astria Therapeutics

Series A in 2011
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

Inotek Pharmaceuticals

Series D in 2011
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Ambit Biosciences

Series D in 2011
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Astria Therapeutics

Series A in 2010
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

Corridor Pharmaceuticals

Series A in 2010
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

Astria Therapeutics

Series A in 2010
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

VentiRx Pharmaceuticals

Series A in 2010
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.

Virdante Pharmaceuticals

Series A in 2009
Virdante Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes drugs for autoimmune and inflammatory diseases. It offers antibody and Fc-fusion drugs to treat auto-immune diseases. The company was formerly known as Centaurus Pharmaceuticals and changed its name to Virdante Pharmaceuticals, Inc. in April, 2008. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Corridor Pharmaceuticals

Series A in 2009
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

LigoCyte Pharmaceuticals

Series C in 2009
LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply treating the resulting symptoms. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry.

VaxInnate

Series D in 2009
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

AGTC

Venture Round in 2009
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

NKT Therapeutics

Series A in 2009
NKT Therapeutics is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma and dermatitis.

Melinta Therapeutics

Series D in 2009
Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

Hydra Biosciences

Series D in 2009
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Corridor Pharmaceuticals

Seed Round in 2008
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

BrainCells

Series B in 2008
BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Ambit Biosciences

Series D in 2007
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Altiris Therapeutics

Series B in 2007
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer. The company offers CXCR4 receptor, which acts as a mediator of cellular and chemical trafficking; and Emtriva, which is used for the treatment of HIV Infection. Altiris Therapeutics was founded in 2005 and is based in Atlanta, Georgia.

Inotek Pharmaceuticals

Series C in 2007
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Sequoia Pharmaceuticals

Series C in 2007
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

VaxInnate

Series C in 2006
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Kemia

Series C in 2006
Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

VLST Corporation

Series B in 2006
VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.

Avidia

Series C in 2006
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.

Inotek Pharmaceuticals

Series B in 2005
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Cellective Therapeutics

Acquisition in 2005
Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Avidia

Series B in 2005
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.

Receptor Biologix

Series A in 2005
Receptor Biologix develops receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases. The company is headquartered in Palo Alto, California.

Cellective Therapeutics

Series A in 2004
Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Inotek Pharmaceuticals

Series A in 2004
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

VaxInnate

Series B in 2004
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

AGTC

Venture Round in 2003
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

Tercica

Series B in 2003
Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.

Iomai Corporation

Series C in 2003
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.

Panacea Pharmaceuticals

Series B in 2002
The Company has collaborated with M.D. Anderson Cancer Center in Houston, Texas; Massachusetts Institute of Technology in Cambridge, Massachusetts; and Rhode Island Hospital/Brown University in Providence, Rhode Island where teams of researchers are continuing advances on the Company's core technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.